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BC

:   breast cancer

BER

:   base excision repair

CI

:   confidence interval

CISH

:   chromogenic in situ hybridization

DSB

:   double strand break

ER

:   estrogen receptor

FA

:   Fanconi anemia

HR

:   hazard ratio

HRM

:   high resolution melt

IHC

:   immunohistochemistry

KBCP

:   Kuopio breast cancer project

NHEJ

:   non‐homologous end joining

PARP

:   poly(ADP‐ribose) polymerase

PR

:   progesterone receptor

SSB

:   single strand break

TNBC

:   triple‐negative breast cancer

Breast cancer is the most common cancer among women worldwide, and also the leading cause of female cancer death.[1](#ijc30394-bib-0001){ref-type="ref"} Most breast cancer cases are sporadic, but around 15% have familial background. Hereditary predisposition to breast cancer is caused by variation in multiple genes commonly involved in DNA repair, especially with homologous recombination repair pathway.[2](#ijc30394-bib-0002){ref-type="ref"} Recently, we identified a new breast cancer allele in the Finnish population in the *FANCM* gene, that functions in the Fanconi Anemia (FA) DNA repair pathway. The *FANCM* c.5101C \> T (p.Q1701X, rs147021911) nonsense mutation increased the risk of breast cancer over twofold, and 3.5‐fold increased frequency was seen among the triple‐negative breast cancer (TNBC) cases.[3](#ijc30394-bib-0003){ref-type="ref"}

Predisposing mutations may associate with specific breast cancer phenotype or subgroup, as well as with patient prognosis and treatment outcome. *CHEK2* and *PALB2* truncating mutations, as well as *FANCM* c.5101C \> T mutation, confer moderate risk for breast cancer, with a higher risk among patients with family history of breast cancer.[3](#ijc30394-bib-0003){ref-type="ref"} ^--^ [7](#ijc30394-bib-0007){ref-type="ref"}

*CHEK2* c.1100delC and *PALB2* c.*1592delT* mutations are associated also with an increased risk of breast cancer death or second breast cancer. Among patients with ER positive breast cancer, *CHEK2* c.1100delC heterozygosity is associated with 1.6‐fold risk of breast cancer specific death and 3.5‐fold risk of a second breast cancer.[8](#ijc30394-bib-0008){ref-type="ref"}, [9](#ijc30394-bib-0009){ref-type="ref"} A significant proportion of PALB2 tumors are triple‐negative and the PALB2 mutation carriers have about 2‐fold increased risk of breast cancer death, independently of the triple‐negative status.[7](#ijc30394-bib-0007){ref-type="ref"}, [10](#ijc30394-bib-0010){ref-type="ref"}

Here, we studied tumor characteristics, patient survival, and treatment outcome associated with the *FANCM* c.5101C \> T mutation among 3,933 breast cancer patients in four breast cancer patient series from Finland. In addition, we examined the nuclear immunohistochemical staining of DNA repair markers in the mutation carrier and non‐carrier tumors from 1,240 invasive breast cancer cases.

Material and Methods {#ijc30394-sec-0002}
====================

Subjects {#ijc30394-sec-0003}
--------

### Helsinki breast cancer series {#ijc30394-sec-0004}

The unselected breast cancer patient samples from Helsinki were collected at Helsinki University Central Hospital. From this cohort, 884 samples, including 79% of all consecutive, newly diagnosed breast cancer cases during the collection periods were collected at Department of Oncology in 1997--1998 and 2000.[11](#ijc30394-bib-0011){ref-type="ref"}, [12](#ijc30394-bib-0012){ref-type="ref"} In addition, 986 samples, including 87% of all consecutive, newly diagnosed breast cancer cases were collected at Department of Surgery in 2001--2004.[13](#ijc30394-bib-0013){ref-type="ref"} Of these series, 397 cases had family history of breast cancer.

Additional familial breast cancer series was collected at Helsinki University Central Hospital Departments of Oncology and Clinical Genetics.[13](#ijc30394-bib-0013){ref-type="ref"}, [14](#ijc30394-bib-0014){ref-type="ref"} When combining the unselected and the additional familial samples, 524 patients had strong family history with at least three breast or ovarian cancers among first or second degree relatives (including the proband) and 568 patients had at least one first degree relative affected with breast or ovarian cancer. All the patients with strong family history were tested negative for *BRCA1/2* mutations and the patients with one affected relative were tested negative for Finnish *BRCA1/2* founder mutations as previously described.[5](#ijc30394-bib-0005){ref-type="ref"}, [15](#ijc30394-bib-0015){ref-type="ref"}, [16](#ijc30394-bib-0016){ref-type="ref"} Only invasive cases were included in the analyses (*N* = 2,337).

All samples are genomic DNA isolated from peripheral blood. The patient genealogies were confirmed with population registries or hospital records and cancer diagnoses through the hospital records and the Finnish Cancer Registry. ER and progesterone hormone receptor (PR) status (positive when \>10% of cells were stained) and tumor histology information were collected from pathology reports, HER2‐status is based on immunohistochemistry and gene amplification as described earlier.[17](#ijc30394-bib-0017){ref-type="ref"}, [18](#ijc30394-bib-0018){ref-type="ref"}, [19](#ijc30394-bib-0019){ref-type="ref"} Information on breast cancer death was obtained from the Finnish Cancer Registry.

### Tampere breast cancer series {#ijc30394-sec-0005}

The unselected breast cancer patient samples from Tampere area were collected in 1997--1999 and additional 336 incident cases in 1996--2004 at Tampere University Hospital as previously described.[11](#ijc30394-bib-0011){ref-type="ref"}, [13](#ijc30394-bib-0013){ref-type="ref"} Only invasive cases were included in the analysis (*N* = 650). All samples are genomic DNA isolated from peripheral blood. ER and PR hormone receptor status (positive when \>10% of cells were stained), HER2‐status, and other clinicopathological information was obtained from patient and pathology reports and information on breast cancer death from the Finnish Cancer Registry.

### Oulu breast cancer series {#ijc30394-sec-0006}

The unselected breast cancer patient samples from Northern Finland were collected at the Oulu University Hospital between the years 2000 and 2007. Only invasive cases were included in the analysis (*N* = 516). All samples are genomic DNA isolated from peripheral blood. HER2‐status was studied by means of immunohistochemistry (positivity defined as weak, moderate or strong levels of staining and negativity completely negative staining) and chromogenic *in situ* hybridization (CISH). ER and PR hormone receptor status (positive when \>10% of cells were stained) and tumor histology information was collected from the pathology reports as described earlier.[20](#ijc30394-bib-0020){ref-type="ref"}, [21](#ijc30394-bib-0021){ref-type="ref"} Information on breast cancer death was obtained from the Oulu University Hospital.

### Kuopio breast cancer series {#ijc30394-sec-0007}

For this study a sample set was used from The Kuopio Breast Cancer Project (KBCP), a prospective population‐based case‐control study conducted in 1990--1995. Women entering Kuopio University Hospital due to breast symptoms were invited to take part in the study at their first visit to the hospital. Altogether 516 women out of 1,919 were eventually diagnosed to have breast cancer. Hospital registries were used to collect information concerning clinicopathological features of the breast cancer, surgical and oncological treatments, and follow‐up.[22](#ijc30394-bib-0022){ref-type="ref"}, [23](#ijc30394-bib-0023){ref-type="ref"} ER and PR hormone receptors were classified as positive if the percentage of positive cells with nuclear staining was ≥ 10%. HER2 status assessment was conducted by immunohistochemistry (IHC). Samples with IHC score 2+ or 3+ were classified as HER2 positive (HER2+). Altogether, 430 female patients with invasive breast cancer were included in the survival analysis. All samples are genomic DNA isolated from peripheral blood.

This study was performed with informed consent from the patients and permission from the ethics committees of Helsinki University Hospital, Oulu University Hospital, Tampere University Hospital, University of Eastern Finland, and Kuopio University Hospital Board on Research Ethics.

Genotyping {#ijc30394-sec-0008}
==========

*FANCM* c.5101C \> T genotyping for the Helsinki and Tampere sample sets was performed with Sequenom MassARRAY system as previously described[3](#ijc30394-bib-0003){ref-type="ref"} and for Oulu and Kuopio sample sets by using PCR‐based high resolution melt (HRM)---analysis and Sanger sequencing. The HRM PCR reactions were performed in 96 well plates using Type‐it HRM PCR Kit (Qiagen, Hilden, Germany) and CFX96 Real‐Time PCR Detection System (CFX96, Bio‐Rad, Hercules, CA). Primers used for the genotyping and sequencing *FANCM* c. 5101C \> T mutation for Oulu and Kuopio cohorts were: F: 5\'TCAAGTGAGGAGGAGAACAATG3\', R: 5\'TCAGCGATGTCTGTTTGCTC3\'.

Statistical Analyses {#ijc30394-sec-0009}
====================

All four datasets including altogether 3,933 invasive breast cancer patients from Helsinki, Tampere, Oulu, and Kuopio areas of Finland, were pooled for statistical analyses. All statistical analyses were performed using the R version 3.0.2 statistical software (<http://www.r-project.org>/). Kaplan--Meier survival curves and uni and multivariate Cox\'s proportional hazard models were used to estimate the hazard ratios and confidence intervals for survival and forest plots were drawn for visualization. All analyses were stratified by the study. The primary end point of the survival analyses was breast cancer death with 10‐year follow‐up time. In addition, 5‐year survival analysis with local recurrence as an endpoint was used for survival analyses in the radiotherapy‐based subgroups in the Helsinki data set (*N* = 2,337), where the information about local recurrence of the disease was available. Time‐to‐event was calculated from the date of the patient diagnosis and to account for the latency between diagnosis and recruitment into the study, all follow‐up times were left‐truncated. Cases with missing data were excluded from the analyses.

The multivariate analyses included the common clinically relevant factors (ER, grade, tumor size, nodal status) and/or cancer treatments (radiotherapy, endocrine therapy, and chemotherapy) as categorical co‐variates and were stratified by the study; inclusion of the study as a categorical co‐variate did not affect the result. In addition, the *FANCM* c.5101C \> T genotype from the pooled data set was fitted into two Cox\'s proportional hazard models in order to test the interaction between the mutation and radiotherapy treatment. One model included the treatment and *FANCM* c.5101C \> T genotype as individual covariates and the other included an interaction term between these two. Two‐way anova was used as a likelihood‐ratio test to compare the two models.[24](#ijc30394-bib-0024){ref-type="ref"}, [25](#ijc30394-bib-0025){ref-type="ref"}

The *p*‐values for comparisons of histopathological features of mutation carriers and non‐carriers were calculated with Pearson\'s chi squared test or Fisher exact test (for *n* ≤ 5). Logistic regression was used for histopathological features with more than two categories. *p*‐values \<0.05 were considered statistically significant.

To test whether *FANCM* mutation status correlates with immunohistochemical expression of markers involved in DNA damage response and repair, we analyzed a number of markers that have been stained and scored as described in our previous studies: BRCA1, FANCD2, RAD51, XPF, PAR[26](#ijc30394-bib-0026){ref-type="ref"}; ATM,[18](#ijc30394-bib-0018){ref-type="ref"} gamma‐HA2X,[27](#ijc30394-bib-0027){ref-type="ref"} and TP53.[28](#ijc30394-bib-0028){ref-type="ref"} For the continuously scored markers (BRCA1, FANCD2, RAD51, XPF, and PAR; % positive nuclei and staining intensity score as determined by automated analysis), association with *FANCM* mutation status was tested using a Kruskal--Wallis test. All other markers used categorical scoring and a *χ* ^2^ test was employed as the test for association. Further information is available in Supporting Information Appendix.

Results {#ijc30394-sec-0010}
=======

All survival analysis results are based on the 3,933 invasive breast cancer cases in the pooled data set with 581 breast cancer deaths, except the survival analysis among radiotherapy‐based subgroups with local recurrence as an endpoint is based on the Helsinki data set with 2,337 invasive samples, including 344 breast cancer deaths. The pooled data set includes 101 *FANCM* c.5101C \> T mutation carriers and 3,832 non‐carriers, Helsinki data set includes 61 mutation carriers and 2,276 non‐carriers. The tumor characteristics of the patients and detailed description of all the datasets used are presented in Table [1](#ijc30394-tbl-0001){ref-type="table-wrap"}.

###### 

Description of the patient data sets used in this study

                                         **Helsinki**      **Tampere**       **Oulu**          **Kuopio**
  -------------------------------------- ----------------- ----------------- ----------------- -----------------
  **No. of cases**                       2,337             650               516               430
  **No. of mutation carriers**           61 (2.6%)         26 (4%)           5 (1%)            9 (2%)
  **Vital status**                                                                             
  Alive                                  1,482 (64%)       448 (69%)         362 (70%)         176 (41%)
  Deceased: all‐cause                    511 (21%)         118 (18%)         94 (18%)          161 (37%)
  Deceased: breast cancer                344 (15%)         84 (13%)          60 (12%)          93 (22%)
  **Follow‐up mean ±SD (years)**         8.16 ± 2.4        7.44 ± 2.13       5.17 ± 2.92       7.78 ± 3.08
  **Age at diagnosis, mean \[range\]**   56.3 \[21--95\]   58.9 \[30--88\]   57.4 \[28--92\]   58.1 \[23--91\]
  **Estrogen receptor**                                                                        
  Negative                               430 (18%)         128 (20%)         96 (19%)          101 (23%)
  Positive                               1,803 (77%)       508 (78%)         385 (75%)         300 (70%)
  Missing data                           104 (5%)          14 (2%)           35 (7%)           29 (7%)
  **Grade**                                                                                    
  1                                      580 (25%)         197 (30%)         76 (15%)          115 (27%)
  2                                      980 (42%)         226 (35%)         212 (41%)         196 (46%)
  3                                      651 (28%)         133 (20%)         177 (34%)         115 (27%)
  Missing data                           126 (5%)          94 (14%)          51 (10%)          4 (1%)
  **T/tumor size category**                                                                    
  1                                      1,409 (60%)       401 (62%)         238 (46%)         229 (53%)
  2                                      743 (32%)         213 (33%)         226 (44%)         161 (37%)
  3                                      69 (3%)           24 (4%)           15 (3%)           23 (5%)
  4                                      82 (4%)           --                --                17 (4%)
  Missing data                           34 (1%)           12 (2%)           37 (7%)           --
  **N (nodal metastasis)**                                                                     
  Negative                               1,263 (54%)       390 (69%)         265 (51%)         251 (58%)
  Positive                               1,036 (44%)       260 (40%)         216 (42%)         171 (40%)
  Missing data                           38 (2%)           --                35 (7%)           8 (2%)
  **M (distant metastasis)**                                                                   
  Negative                               2,253 (96.5%)     630 (97%)         492 (95%)         419 (97%)
  Positive                               73 (3%)           12 (2%)           24 (5%)           11 (3%)
  Missing data                           11 (0.5%)         8 (1%)            --                --
  **Histological type**                                                                        
  Ductal                                 1,597 (68%)       537 (83%)         371 (71%)         281 (65%)
  Lobular                                470 (20%)         86 (13%)          78 (15%)          73 (17%)
  Medullar                               29 (1%)           --                2 (1%)            8 (2%)
  Other                                  240 (10%)         18 (3%)           30 (6%)           68 (16%)
  NA                                     1                 9 (1%)            35 (7%)           --
  **Radiotherapy**                                                                             
  Yes                                    1,829 (78%)       493 (76%)         423 (82%)         251 (58%)
  No                                     443 (19%)         155 (24%)         87 (17%)          179 (42%)
  Missing data                           65 (3%)           2                 6 (1%)            --
  **Chemotherapy**                                                                             
  Yes                                    870 (37%)         131 (20%)         215 (42%)         83 (19%)
  No                                     1,405(60%)        511 (79%)         297 (58%)         347 (81%)
  Missing data                           62 (3%)           8 (1%)            4 (1%)            --
  **Endocrine therapy**                                                                        
  Yes                                    1,055 (45%)       204 (32%)         243 (47%)         105 (24%)
  No                                     1,207 (52%)       444 (68%)         268 (52%)         325 (76%)
  Missing data                           65 (3%)           2                 5 (1%)            --

Histopathological Features of the FANCM C.5101C \> T Positive Tumors {#ijc30394-sec-0011}
====================================================================

The association of the *FANCM* c.5101C \> T mutation with histopathological features of the tumors was studied in the pooled data among all cases and separately among ER positive cases (Table [2](#ijc30394-tbl-0002){ref-type="table-wrap"}). The mutation did not associate with any common clinical feature, however the breast tumors from the c.5101C \> T mutation carriers were more often of triple negative phenotype (*p* = 0.060, compared with tumors from non‐carriers).

###### 

Histopathological features of *FANCM* c.5101C \> T‐mutation carriers and wild type tumors

  Category                              FANCM c.5101C\>T   \%       FANCM wt   \%       *p*         Model
  ------------------------------------- ------------------ -------- ---------- -------- ----------- ---------------------
  **All breast cancer cases**                                                                       
  **Grade**                                                                             **0.263**   Logistic regression
  1                                     25                 26.00%   943        26.00%               
  2                                     36                 37.00%   1,578      44.00%               
  3                                     36                 37.00%   1,040      30.00%               
  **T**                                                                                 **0.255**   Logistic regression
  1                                     53                 53.00%   2,224      59.00%               
  2                                     41                 41.00%   1,302      34.50%               
  3                                     2                  2.00%    129        3.00%                
  4                                     4                  4.00%    95         2.50%                
  **N**                                                                                 **0.380**   Pearson chisq.
  neg                                   52                 52.00%   2,117      56.20%               
  pos                                   48                 48.00%   1,653      43.80%               
  **M**                                                                                 **0.770**   Fisher
  neg                                   99                 99.00%   3,695      96.90%               
  pos                                   2                  1.00%    118        3.10%                
  **ER**                                                                                **0.432**   Pearson chisq.
  neg                                   23                 23.00%   726        19.80%               
  pos                                   77                 77.00%   2,936      80.20%               
  **PR**                                                                                **0.380**   Pearson chisq.
  neg                                   39                 39.00%   1,271      34.80%               
  pos                                   61                 61.00%   2,386      65.20%               
  **Her2**                                                                              **0.167**   Pearson chisq.
  neg                                   67                 90.50%   2,336      91.50%               
  pos                                   7                  9.50%    422        8.50%                
  **TN**                                                                                **0.060**   Pearson chisq.
  TN                                    13                 14.00%   297        8.50%                
  NOT TN                                80                 86.00%   3,215      91.50%               
  **Morphology**                                                                        **0.366**   Logistic regression
  Ductal                                78                 77.00%   2,708      71.50%               
  Lobular                               14                 14.00%   693        18.30%               
  Medullar                              1                  1.00%    38         1.00%                
  Other                                 8                  8.00%    348        9.20%                
  **ER‐positive breast cancer cases**                                                               
  **Grade**                                                                             **0.813**   Logistic regression
  1                                     25                 33.50%   874        31.50%               
  2                                     33                 44.00%   1,379      49.50%               
  3                                     17                 22.50%   524        19.00%               
  ***T***                                                                               **0.279**   Logistic regression
  1                                     45                 57.00%   1,827      63.00%               
  2                                     27                 35.00%   934        32.00%               
  3                                     1                  3.00%    87         3.00%                
  4                                     4                  5.00%    67         2.00%                
  **N**                                                                                 **0.500**   Pearson chisq.
  neg                                   40                 52.50%   1,265      43.50%               
  pos                                   36                 47.50%   1,644      46.50%               
  **M**                                                                                 **0.775**   Fisher
  neg                                   76                 98.70%   2,841      98.00%               
  pos                                   1                  1.30%    65         2.00%                
  **PR**                                                                                **0.754**   Pearson chisq.
  neg                                   17                 22.00%   604        20.00%               
  pos                                   60                 88.00%   2,326      80.00%               
  **Her2**                                                                              **1**       Fisher
  neg                                   52                 91.00%   1,943      90.00%               
  pos                                   5                  9.00%    219        10.00%               
  **Morphology**                                                                        **0.587**   Logistic regression
  Ductal                                56                 73.00%   2,007      68.00%               
  Lobular                               14                 18.00%   635        22.00%               
  Medullar                              0                  0.00%    4          0.00%                
  Other                                 7                  9.00%    286        10.00%               

Abbreviations: T: tumor size class; M: distant metastasis; ER: estrogen receptor; PR: progesterone receptor

FANCM C.5101C \> T Mutation Associates with Breast Cancer Survival {#ijc30394-sec-0012}
==================================================================

To evaluate the association of the *FANCM* c.5101C \> T mutation with the disease outcome, we examined 10‐year breast cancer specific survival by Cox\'s univariate proportional hazard analysis in 3,933 invasive breast cancer patients from Helsinki, Tampere, Oulu, and Kuopio data sets. The mutation was associated with poor breast cancer‐specific survival in the pooled data set stratified for study (HR = 1.66, 95% CI 1.09--2.52, *p* = 0.018). Absolute uncorrected survival rates are illustrated in Figure [1](#ijc30394-fig-0001){ref-type="fig"}a. However, in the multivariate survival analysis including the common clinical features (ER, grade, tumor size, nodal status) and the conventional cancer treatments (radiotherapy, chemotherapy, endocrine treatment) the mutation was not significantly and independently prognostic in the pooled data set (HR = 1.44, 95% CI 0.91--2.26, *p* = 0.133) (Supporting Information Table 1).

![Kaplan--Meier plots of cumulative survival for breast cancer death in 10 years. Absolute uncorrected survival rates are presented among the pooled data set (HR = 1.62, 95% CI 1.07--2.46, *p* ~Cox\'s\ regression~ = 0.023; (*a*) and among ER‐positive patients (HR = 1.8, 95% CI 1.09--2.98, *p* ~Cox\'s\ regression~ = 0.021; (*b*) Results for survival analysis among familial cases (*C*) from Helsinki.](IJC-139-2760-g001){#ijc30394-fig-0001}

As the mutation associates with triple‐negative phenotype with poor survival as such, we analyzed the survival specifically also among ER positive cases. The mutation associated with reduced survival also in the ER‐positive group of patients in the pooled data set stratified for study (HR = 1.8, 95% CI 1.09--2.98, *p* = 0.021). Absolute uncorrected survival rates are illustrated in Figure [1](#ijc30394-fig-0001){ref-type="fig"}b. Furthermore, as the *FANCM* c.5101C \> T mutation associates with familial breast cancer risk, we performed the survival analysis for the invasive familial cases (*N* = 1,006) among the Helsinki dataset in which familial status was available for the samples. The breast cancer specific survival was worse for mutation carriers among patients with family history of the disease (HR = 2.93, 95% CI 1.5--5.76, *p* = 1.80 × 10^−3^; Fig. [1](#ijc30394-fig-0001){ref-type="fig"}c).

Survival in Subgroups Defined by Tumor Phenotype and Treatment {#ijc30394-sec-0013}
==============================================================

To examine the survival effect of the *FANCM* c.5101C \> T mutation in more detail, we performed univariate Cox\'s proportional hazard analysis (endpoint: breast cancer death in 10 years) in subgroups based on the tumor phenotype (ER, PR, TN, nodal status, tumor size, grade) among the pooled data set (*N* = 3,933). In addition, we performed univariate Cox\'s proportional hazard analysis by the conventional cancer treatment options (endocrine treatment, radiotherapy, and/or chemotherapy) to examine the treatment outcome of the *FANCM* c.5101C \> T mutation carriers. Forest plot was drawn for visualizing hazard ratios and confidence intervals (Fig. [2](#ijc30394-fig-0002){ref-type="fig"}). As the worse survival was also seen among the ER‐positive patients, we performed similar subgroup analyses (PR, TN, nodal status, tumor size, grade, and the anticancer treatments) among ER‐positive patients (*N* = 3,013) (Supporting Information Fig. 1). Heterogeneity in the survival effect was seen for the c.5101C \> T mutation carriers related to radiotherapy treatment, with significantly reduced survival especially among patients who had not received radiotherapy (HR = 3.43, 95% CI 1.6--7.34, *p* = 1.50 × 10^−3^) but not among radiotherapy treated patients (HR = 1.35, 95% CI 0.82--2.23, *p* = 0.237).

![Forest plot of hazard ratios and their confidence intervals for the *FANCM* c.5101 C \> T mutation in the pooled data set and in different subgroups including the clinical factors and conventional cancer treatments. The Cox proportional hazard model was used for 10‐year breast‐cancer specific survival. Horizontal lines represent 95% confidence intervals. ER = estrogen receptor, PR = progesterone receptor, TN =triple negative, N = nodal metastasis status. All cases = all cases after samples with missing data are excluded.](IJC-139-2760-g002){#ijc30394-fig-0002}

To further examine the radiotherapy outcome among the c.5101C \> T carriers, we performed survival analysis with local recurrence (within 5 years) as an endpoint in the Helsinki data set where the recurrence information was available (*N* = 2,337). Increased risk for local recurrence was observed for mutation carriers who had not received radiotherapy (HR = 6.19, 95% CI 1.46--26.2, *p* = 0.013, Supporting Information Table 2) but not among radiotherapy treated patients (HR = 0.98, 95% CI = 0.24--4.00, *p* = 0.979). In the multivariate model, the *FANCM* c.5101C \> T mutation is only borderline significant (*p* = 0.086), however the hazard ratios remain consistent.

Next, we tested interaction between *FANCM* c.5101C \> T genotype and radiotherapy treatment with Cox\'s proportional hazard model stratified with study among pooled data set, including 2,996 patients who had received radiotherapy and 864 who had not (Table [3](#ijc30394-tbl-0003){ref-type="table-wrap"}A). A significant interaction was seen between the mutation and radiotherapy treatment (*p* = 0.032), with a protective hazard ratio (HR = 0.37, 95% CI 0.15--0.92). A likelihood‐ratio test comparing models with interaction term and model with independent covariates displayed an interactive effect between the covariates (*p* ~(interaction)~=0.040). These results suggest that *FANCM*‐mutation positive breast cancer patients may benefit from radiotherapy more than non‐carriers, an issue that should be further investigated to clarify the absolute benefits from radiotherapy to such patients.

###### 

A\) Cox\'s proportional hazard model to test the interaction between radiotherapy treatment and *FANCM* c.5101C \> T mutation with breast cancer death as an endpoint; B) Local recurrence as an endpoint

  Covariate                                HR       *p*             95% CI        Endpoint
  ---------------------------------------- -------- --------------- ------------- ------------------------------
  **A**                                                                           
  ** Model 1: no interaction**                                                    Breast cancer death (10 yrs)
  **  **RS147021911                        1.71     0.011           1.13--2.60    
  **  **Radiotherapy                       0.70     1.0 × 10^−4^    0.58‐0.84     
  **Covariate**                            **HR**   ***p***         **95% CI**    **Endpoint**
  ** Model 2: interaction**                                                       Breast cancer death (10 yrs)
  **  **RS147021911                        3.72     7.00 × 10^−4^   1.74‐7.95     
  **  **Radiotherapy                       0.72     8.40 × 10^−4^   0.59--0.87    
  **  **RS147021911:Radiotherapy           0.37     0.032           0.15--0.92    
  **  **Likelihood ratio test *p* values            0.040                         
  **B**                                                                           
  **Covariate**                            **HR**   ***p***         **95% CI**    **Endpoint**
  ** Model 1: no interaction**                                                    Local recurrence (5 yrs)
  **  **RS147021911                        1.71     0.298           0.62--4.64    
  **  **Radiotherapy                       0.48     1.05 × 10^−3^   0.31--0.75    
  **Covariate**                            **HR**   ***p***         **95% CI**    **Endpoint**
  ** Model 2: interaction**                                                       Local recurrence (5 yrs)
  **  **RS147021911                        5.96     1.50 × 10^−3^   1.42--25.11   
  **  **Radiotherapy                       0.52     4.05 × 10^−3^   0.33--0.81    
  **  **RS147021911:Radiotherapy           0.16     0.080           0.02--1.23    
  **  **Likelihood ratio test *p* values            0.090                         

We further studied the survival interaction of *FANCM* mutation with radiotherapy using similar interaction model with local recurrence (within 5 years) as an endpoint in the Helsinki data set (*N* = 2,069) (Table [3](#ijc30394-tbl-0003){ref-type="table-wrap"}B). Due to the smaller sample size and thus loss of statistical power, the significance of the interactive effect is not apparent (likelihood‐ratio test *p* values 0.090). However, even more pronounced protective hazard ratio was seen for *FANCM* c.5101C \> T mutation and radiotherapy interaction (HR = 0.16), compared to significantly increased hazard ratio for mutation alone (HR = 5.96).

Immunohistochemical Analyses {#ijc30394-sec-0014}
============================

In the association analysis between *FANCM* c.5101C \> T mutation status and DNA repair related immunohistochemical markers, a statistically significant association was detected between nuclear poly‐ADP‐ribose (PAR; a measurement of PARP activity) staining and mutated *FANCM*. PAR staining was reduced in *FANCM* c.5101C \> T mutation carrier tumors, both in terms of the proportion of positively stained tumor nuclei (*p* = 0.016, Kruskal‐Wallis test) and staining intensity (*p* = 0.011, Kruskal--Wallis test) (Supporting Information Fig. 2). No other immunohistochemical markers were associated with mutated *FANCM* (Supporting Information Table 3).

Discussion {#ijc30394-sec-0015}
==========

This study evaluated the survival association, tumor characteristics, and treatment outcome for Finnish breast cancer patients carrying the *FANCM* c.5101C \> T mutation. We detected an association between the *FANCM* c.5101C \> T mutation and adverse breast cancer outcome (HR = 1.66, 95% CI 1.09 -- 2.52, *p* = 0.018, *N* = 3,832 \[non‐carriers\], *N* = 101 \[mutation carriers\]). The breast cancer specific survival was worse among familial cases (HR = 2.93, 95% CI 1.5--5.76, *p* = 1.80 × 10^−3^, *N* = 981 \[non‐carriers\], *N* = 25 \[mutation carriers\]).

When examining the tumors of the *FANCM* c.5101C \> T mutation carriers, a borderline significant association of the mutation was seen with triple‐negative tumors (*p* = 0.060, compared with tumors from non‐carriers). This is in line with the previous risk analysis, in which the *FANCM* c.5101C \> T mutation was found to be associated with 3.6‐fold increased risk for triple‐negative subtype of breast cancer.[3](#ijc30394-bib-0003){ref-type="ref"} This type of breast cancer is generally aggressive with poor prognosis and no effective therapies available.[29](#ijc30394-bib-0029){ref-type="ref"} However, our survival analysis indicates that the poor prognosis associated with *FANCM* c.5101C \> T mutation is not only a result of the higher incidence of the triple‐negative tumors, as the mutation also associates with worse survival among the ER‐positive subgroup of patients. Yet in the multivariate survival analysis including conventional prognostic markers and treatments, the *FANCM* c.5101C \> T mutation was not independently prognostic (HR = 1.44, 95% CI 0.91‐2.26, *p* = 0.133).

The comprehensive survival analyses revealed an association with *FANCM* c.5101C \> T mutation and radiotherapy outcome. Interaction analyses with a hazard ratio of 0.37 (95% CI 0.15--0.95, *p* = 0.032) for the mutation:radiotherapy interaction compared to the HR of 3.72 for the mutation alone (95% CI 1.74--7.95, *p* = 7.00 × 10^−4^) in the interaction model indicate that the mutation carriers may benefit from radiotherapy. To this end, we performed the interaction analyses also with local recurrence in five years as an endpoint, as radiotherapy is commonly used to prevent such events. While this interaction model is not statistically significant in the smaller sample set, the more pronounced protective hazard ratio of 0.16 for the radiotherapy and *FANCM* c.5101C \> T interaction further supports our observations that carrying the *FANCM* c. 5101C \> T mutation increases the risk for local recurrence and subsequently also death from breast cancer, however the mutation carriers seem to benefit from postoperative radiotherapy. From the pathobiological point of view, we propose that the increased risk of local recurrence and death may reflect enhanced genomic instability and hence aggressiveness due to impaired DNA repair in the tumors with the *FANCM* c. 5101C \> T mutation. On the positive side, such enhanced genetic instability and suboptimal repair capacity seem to represent a specific vulnerability of such tumors, manifest particularly after an extra burden of difficult‐to repair DNA damage caused by ionizing radiation treatment. Overall, these results are especially interesting, as markers associated with radiotherapy treatment outcome for cancer patients have not been previously described. However, further studies in larger datasets are needed to validate the radiotherapy outcome for *FANCM* mutation carriers.

FANCM is a multifunctional protein, acting as an anchor protein for both Fanconi Anemia and Bloom syndrome complexes, two molecular pathways that functionally overlap in these genetic disorders.[30](#ijc30394-bib-0030){ref-type="ref"}, [31](#ijc30394-bib-0031){ref-type="ref"}, [32](#ijc30394-bib-0032){ref-type="ref"} As a part of the FA pathway, FANCM operates in the interstrand crosslink repair to facilitate various DNA repair processes, such as homologous recombination and non‐homologous end‐joining (NHEJ) pathway.[30](#ijc30394-bib-0030){ref-type="ref"}, [33](#ijc30394-bib-0033){ref-type="ref"} Inactivation of the FA pathway leads to hypersensitivity to DNA crosslinking agents, and in the absence of FANCM, the formation of the FA and Bloom\'s complexes is unsuccessful and this may explain the tumorigenetic characteristics of defective FANCM protein.[32](#ijc30394-bib-0032){ref-type="ref"} Interestingly, in addition to *BRCA*‐genes, recent studies link several Fanconi anemia pathway genes also with sensitivity to PARP inhibition, including *PALB2*, *RAD51C,* and *SLX4,* [34](#ijc30394-bib-0034){ref-type="ref"}, [35](#ijc30394-bib-0035){ref-type="ref"}, [36](#ijc30394-bib-0036){ref-type="ref"} as well as *FANCM*.[35](#ijc30394-bib-0035){ref-type="ref"} Mutations in *FANCM* were found to cause hypersensitivity to PARP inhibitors, indicating that FANCM actually has a role in the cellular defense against PARP inhibition.[37](#ijc30394-bib-0037){ref-type="ref"} This may reflect the several roles FANCM has in cells also outside the Fanconi Anemia pathway, including replisome stability and cell cycle checkpoint activation when DNA repair is needed.[38](#ijc30394-bib-0038){ref-type="ref"}, [39](#ijc30394-bib-0039){ref-type="ref"}, [40](#ijc30394-bib-0040){ref-type="ref"}

Taking the DNA repair functions of FANCM in consideration, we examined nuclear immunohistochemical staining profiles of DNA repair markers of the FANCM c.5101C \> T mutation carriers. Among eight examined markers, the mutation was associated with low expression of poly (ADP‐ribose) marker (PAR), which measures the activity of the PARP enzymes participating in DNA repair processes in cells,[41](#ijc30394-bib-0041){ref-type="ref"} indicating that the mutation carriers have decreased PARP‐activity. It must be noted that our immunohistochemical method measures the overall poly(ADP‐ribosyl)ation levels in tumor nuclei, and is therefore not specific to any particular PARP enzyme or biological process. The best known example of PARylation occurs in response to DNA damage, where the binding and activity of PARP promotes DNA repair through the single‐strand break (SSB), double‐strand break (DSB), or base excision repair (BER) pathways.[42](#ijc30394-bib-0042){ref-type="ref"} In the case of excessive DNA damage, hyper‐PARylation may also be a signal for cell death.[43](#ijc30394-bib-0043){ref-type="ref"} PARylation has additionally been reported to play a role in mitosis, chromatin remodeling, regulation of transcription, and the organization of genomic regulatory regions via insulator elements.[44](#ijc30394-bib-0044){ref-type="ref"} We can therefore only speculate on the specific functional significance of the FANCM‐associated reduction in PARylation observed in our breast tumor samples. We did not detect a change in gamma‐H2AX staining, suggesting that a major quantitative change in overall DNA damage is not the case here. Since both FANCM and PARP are involved in resolving replication stress,[45](#ijc30394-bib-0045){ref-type="ref"}, [46](#ijc30394-bib-0046){ref-type="ref"}, [47](#ijc30394-bib-0047){ref-type="ref"} it is possible that the *FANCM* c.5101C \> T mutation‐associated reduction in PAR staining indicates a replication stress sensitive phenotype that would respond strongly to the extreme replication stress caused by radiation therapy. While the causal relationship of *FANCM* with reduced PARylation levels remains unclear, our data may have therapeutic implications.[27](#ijc30394-bib-0027){ref-type="ref"}, [48](#ijc30394-bib-0048){ref-type="ref"} Given the role of FANCM in resolving replication stress, the FANCM‐mutant tumors may be especially sensitive to drugs that further exacerbate the extent of replication stress, such as PARP inhibitors. Based on our present results and the emerging knowledge in the field, we suggest that the subset of FANCM‐mutant tumors may be particularly vulnerable to PARP inhibitors, used either as a monotherapy or, as our data indicate, combined with radiotherapy. Future preclinical and clinical studies should test the feasibility of these conceptually plausible options.

Conclusions {#ijc30394-sec-0016}
===========

Our findings indicate that the *FANCM* c.5101C \> T mutation in Fanconi Anemia pathway associates with the disease outcome of breast cancer. Based on the large series of Finnish breast cancer patients, we have shown here that the mutation carriers have worse long‐term survival and increased risk for local recurrence, however the survival may be improved with radiotherapy. Further analyses in larger datasets are warranted to clarify the survival effects and functional mechanisms associated with the mutation, especially on the efficacy of radiotherapy. Such studies may eventually help to understand the biological mechanisms affecting tumor progression and further support efforts for creating more targeted treatment combinations and risk estimation.
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